Related Experiment Video
Updated: Mar 19, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Neoadjuvant chemoimmunotherapy improves response rates in head and neck cancer
Jennifer L Anderson1, Andrew G Sikora1
1The University of Texas MD Anderson Cancer Center Houston, TX United States.
None:
Despite the recent approval of perioperative pembrolizumab for locally advanced, resectable head and neck squamous cell carcinoma, response rates to immunotherapy are low. A recent single-arm phase II trial of neoadjuvant nivolumab in combination with carboplatin and paclitaxel demonstrated improved pathologic response rates compared to either chemotherapy or immunotherapy alone.
Related Concept Videos
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistent Cancers
Treatment Resistant Cancers

